TABLE 3.
Outcomes for evaluable patientsa
| Dosing group | Change in serum creatinine concn (mg/dl)b
|
Duration of therapy (days)
|
Cumulative dose
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gentamicin and tobramycin
|
Amikacinc
|
|||||||||
| Mean ± SD | Range | Mean ± SD | Range | No. of patients | Mean ± SD dose (mg) | Dose range (mg) | No. of patients | Mean ± SD dose (mg) | Dose range (mg) | |
| Once daily | 0.2 ± 0.4 | 0–2.1 | 8.2 ± 6.2 | 3–39 | 36 | 2,133 ± 2,233 | 720–13,600 | 3 | 11,250 ± 3,470 | 7,000–15,500 |
| Twice daily | 0.1 ± 0.2 | 0–0.5 | 10.6 ± 9.7 | 3–52 | 33 | 3,110 ± 2,619 | 800–13,400 | 2 | 16,500 ± 10,750 | 5,750–27,250 |
a
No statistically significant differences were present between the two treatment groups.
b
Change in serum creatinine = (peak serum creatinine concentration) − (baseline creatinine concentration).
c
Data were not available for one patient who received amikacin.